Drug Trial Radar · NCT07288359
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
205
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
May 9, 2031
Study completion May 9, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Conditions
- Advanced HR+/HER2- Breast Cancer
- Advanced CCNE1-amplified Solid Tumors
- Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858Drug
Experimental
FulvestrantDrug
Approved medication
LetrozoleDrug
Approved medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: 28 days
- Phase I and phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 2 years
- Phase I and phase II: Frequency of dose interruptions, reductions and discontinuationsTime frame: Up to approximately 2 years
- Phase I and phase II: Dose intensityTime frame: Up to approximately 2 years
Locations
16 sites in 11 countries. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia · Recruiting
Tennessee Oncology PLLC
Nashville, Tennessee · Recruiting
START
San Antonio, Texas · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Olomouc, Czechia · Recruiting
Novartis Investigative Site
Odense C, Denmark · Recruiting
Novartis Investigative Site
Pierre-Bénite, France · Recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
Jena, Thuringia, Germany · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Milan, MI, Italy · Recruiting
Novartis Investigative Site
Kyoto, Japan · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.